Subscribe
This Danish drug giant has suffered plenty of misfortune, but better times lie ahead
The managers strike the right balance between high payouts and making sure your capital grows too
Rate cuts and deregulation could bolster this bank that鈥檚 already punching above its weight
The company isn鈥檛 merely recovering 鈥� the main division is now worth more than the group itself
There are plenty of execution risks in its grand transformation plan
A couple of pivotal years should see the Swiss giant through its patent erosion
This trust is built to hold up well in a crisis
Poor sentiment and an unusual structure mean this rejuvenated media stock trades at an exceptionally low discount
Shares are already up 150 per cent, but there鈥檚 more to come once legacy issues are resolved
The group鈥檚 data and analytics business provides a deep moat to fend off potential disrupters
